carbamates has been researched along with Akinetic-Rigid Variant of Huntington Disease in 3 studies
Excerpt | Relevance | Reference |
---|---|---|
" In the R6/2 mouse HD model, induced DREAM haplodeficiency or blockade of DREAM activity by chronic administration of the drug repaglinide delayed onset of motor dysfunction, reduced striatal atrophy, and prolonged life span." | 1.43 | Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease. ( Arrabal, MD; Casado-Vela, J; Cercós, P; De la Cruz, A; Dopazo, XM; González, P; González, T; Gutierrez-Rodriguez, M; Higueras, E; Li, JY; Mellström, B; Morón-Oset, J; Naranjo, JR; Oliveros, JC; Prieto, A; Rábano, A; Valenzuela, C; Villar, D; Zhang, H, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
López-Hurtado, A | 1 |
Burgos, DF | 1 |
González, P | 2 |
Dopazo, XM | 2 |
González, V | 1 |
Rábano, A | 2 |
Mellström, B | 2 |
Naranjo, JR | 2 |
Zhang, H | 1 |
Villar, D | 1 |
Morón-Oset, J | 1 |
Higueras, E | 1 |
Oliveros, JC | 1 |
Arrabal, MD | 1 |
Prieto, A | 1 |
Cercós, P | 1 |
González, T | 1 |
De la Cruz, A | 1 |
Casado-Vela, J | 1 |
Valenzuela, C | 1 |
Gutierrez-Rodriguez, M | 1 |
Li, JY | 1 |
Rot, U | 1 |
Kobal, J | 1 |
Sever, A | 1 |
Pirtosek, Z | 1 |
Mesec, A | 1 |
3 other studies available for carbamates and Akinetic-Rigid Variant of Huntington Disease
Article | Year |
---|---|
Inhibition of DREAM-ATF6 interaction delays onset of cognition deficit in a mouse model of Huntington's disease.
Topics: Activating Transcription Factor 6; Animals; Carbamates; Cognition Disorders; Disease Models, Animal; | 2018 |
Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease.
Topics: Activating Transcription Factor 6; Animals; Carbamates; CHO Cells; Corpus Striatum; Cricetulus; Dise | 2016 |
Rivastigmine in the treatment of Huntington's disease.
Topics: Carbamates; Cholinesterase Inhibitors; Humans; Huntington Disease; Phenylcarbamates; Rivastigmine | 2002 |